Cypress Capital Management (Wyoming)’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-24
| Closed | -$4K | – | 357 |
|
|
2018
Q3 | $4K | Hold |
24
| – | – | ﹤0.01% | 308 |
|
|
2018
Q2 | $3K | Hold |
24
| – | – | ﹤0.01% | 306 |
|
|
2018
Q1 | $2K | Hold |
24
| – | – | ﹤0.01% | 293 |
|
|
2017
Q4 | $2K | Hold |
24
| – | – | ﹤0.01% | 298 |
|
|
2017
Q3 | $2K | Hold |
24
| – | – | ﹤0.01% | 259 |
|
|
2017
Q2 | $1.82K | Hold |
24
| – | – | ﹤0.01% | 252 |
|
|
2017
Q1 | $1.59K | Sell |
24
-2,244
| -99% | -$148K | ﹤0.01% | 257 |
|
|
2016
Q4 | $145K | Buy |
2,268
+1,867
| +466% | +$119K | 0.15% | 79 |
|
|
2016
Q3 | $25.5K | Buy |
+401
| New | +$25.5K | 0.03% | 147 |
|
|
2016
Q2 | – | Sell |
-425
| Closed | -$28.4K | – | 241 |
|
|
2016
Q1 | $28.4K | Buy |
425
+185
| +77% | +$12.4K | 0.04% | 129 |
|
|
2015
Q4 | $16.3K | Hold |
240
| – | – | 0.02% | 164 |
|
|
2015
Q3 | $12.8K | Buy |
+240
| New | +$12.8K | 0.02% | 171 |
|